CLBR001 CAR-T for Non-Hodgkin's Lymphoma
Recruiting in Palo Alto (17 mi)
+7 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Calibr, a division of Scripps Research
No Placebo Group
Trial Summary
What is the purpose of this trial?This trial involves monitoring patients who received a special cancer treatment using their own modified immune cells. These patients are followed for an extended period to check for safety and effectiveness. The treatment works by reprogramming the patient's immune cells to better fight cancer and has shown promising results.
Eligibility Criteria
This trial is for patients who have received at least one dose of CLBR001 CAR-T cells for various types of B-cell lymphomas and leukemias. Participants must be able to give informed consent and follow the study's visit schedule and requirements.Participant Groups
The study follows up long-term with patients treated with genetically modified autologous CLBR001 CAR-T cells, possibly in combination with SWI019, to monitor ongoing effects after their initial treatment.
1Treatment groups
Experimental Treatment
Group I: CLBR001 treated patientsExperimental Treatment1 Intervention
Patients who have been administered with CLBR001
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Sarah Cannon Research Institute - Texas Transplant InstituteSan Antonio, TX
City of Hope National Medical CenterDuarte, CA
University of ChicagoChicago, IL
Sarah Cannon Research Institute - Tennessee OncologyNashville, TN
More Trial Locations
Loading ...
Who is running the clinical trial?
Calibr, a division of Scripps ResearchLead Sponsor